Global Influenza Vaccines Market was Worth US$ 3,991.4 Million, and It is Predicted to Grow at a CAGR of 4.4% from 2018 to 2026

Influenza Vaccines

The influenza virus causes a contagious respiratory ailment known as influenza. Fever, cough, muscle and joint discomfort, headache, and severe weakness are all symptoms of influenza. Influenza illness can range from mild to severe, and it can even result in death. According to the World Health Organization (WHO), influenza-related hospitalizations range from 3-5 million instances for serious illness in 2018, while influenza-related deaths range from 290 000 to 650 000.

The Influenza Vaccines Market is growing due to increasing product approval for the vaccine. The demand for improved vaccines is increasing as seasonal influenza virus outbreaks become more common. The market for influenza vaccinations is predicted to rise as the number of licensed products grows. Seqirus Vaccine Limited, for example, got FDA clearance in August 2016 for Afluria Quadrivalent, Afluria Trivalent, Flucelvax Quadrivalent in May 2016, and Fluad in November 2015. 

Increased government initiatives to lead novel vaccine research paths are also likely to drive market expansion. For example, in April 2018, the Bill and Malinda Gates Foundation and Lucy and Larry Page announced a US$ 12 million prize for researchers who can come up with new ideas for flu vaccines that are safe, effective, and inexpensive. Furthermore, the National Institute of Allergy and Infectious Diseases (NIAID) supported a universal influenza vaccine trial in May 2018. Furthermore, the Influenza Vaccines Market is growing due to a government initiative to increase vaccine availability.

In order to avoid influenza infections, vaccines are advised. Inactivated influenza vaccine, adjuvant inactivated influenza vaccine, live attenuated influenza vaccine, and recombinant influenza vaccine are all options for influenza vaccination. The increasing spread of influenza virus epidemics around the world is driving the need for effective influenza vaccination. The key aspect fueling the company's success is a strong product pipeline.

The continual evolution of the influenza virus genetic structure results in the creation of novel viruses that are immune to currently available influenza vaccinations. The Influenza Vaccines Market is projected to face significant headwinds as a result of these constantly evolving viruses. Furthermore, market growth is likely to be hampered by the high cost of vaccine development over the forecast period. Furthermore, increasing the number of strong influenza vaccine pipeline candidates is likely to support market growth. Furthermore, in May 2018, FluGen, Inc., a vaccine development business in the clinical stage, began a clinical trial for the M2SR influenza vaccine.